Tiziana Announces Publication of a Peer Reviewed Article on Data from the Clinical Trial with Intranasally Administered Foralumab, Its Proprietary Fully Human Anti-CD3 Monoclonal Antibody, in Mild to Moderate COVID-19 Patients in Brazil

NEXT STORY
Global $3.5+ Bn microRNA (miRNA) Markets Analysis & Forecasts, 2016-2020 & 2021-2028
PREV STORY
Basilea meldet starke Finanzergebnisse für das erste Halbjahr 2021 mit deutlich erhöhtem Cashflow durch vermarktete Produkte und erhöht finanziellen Ausblick für Gesamtjahr 2021
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Affimed Announces Successful Completion of First Dose Cohort in First-in-Human Phase 1/2A Study of AFM24 for the Treatment of Advanced EGFR-Expressing Solid Tumors Including Colon, Lung and Other Cancers

author_avatar
NASDAQ Market News

New Data Highlighting Itch Reduction with Topical Roflumilast in Multiple Dermatologic Conditions Presented at European Academy of Dermatology and Venereology Congress

author_avatar
NASDAQ Market News

Claritas (formerly Kalytera Therapeutics, Inc.) Announces Addition of Professor Salvatore Cuzzocrea, Ph.D. to the Company’s Board of Directors

author_avatar
NASDAQ Market News